Dr Anna Ralph
Senior clinical research fellow
PhD, Australian National University, 2010; Fellow of the Royal Australasian College of Physicians, 2005; Diploma of Hygiene and Tropical Medicine, University of London, 2002; Master of Public Health, University of Sydney, 1999; Bachelor of Medicine and Bachelor of Surgery, University of New South Wales, 1996; Medical Science Honours Class 1, Australian National University, 1993; Bachelor of Medical Science, University of Tasmania, 1992.
Her research goals are to improve outcomes for people with diseases of poverty including tuberculosis and rheumatic fever. Her offshore research has included studies to improve knowledge of regional tuberculosis pathophysiology, epidemiology and treatment (in Indonesia and Malaysia). Her local research focus is on improving the management of acute rheumatic fever in the Northern Territory.
- L-Arginine and vitamin D adjunctive therapies in pulmonary tuberculosis (2010-2014)
Improving delivery of secondary prophylaxis for rheumatic heart disease: a stepped-wedge, community-randomised trial (2012-2016).
- Ralph, A.P., Waramori G., Pontororing G.J., Kenangalem E., Wiguna A., Sandjaja, Tjitra, E., et al. (2013) L-arginine and Vitamin D adjunctive therapies in pulmonary tuberculosis: a randomised, double-blind, placebo-controlled trial. PLoS ONE, 8(8).
- Ralph, A.P., Lucas, R.M.,& Norval. (2013). Vitamin D and solar ultraviolet radiation in the risk and treatment of tuberculosis. Lancet Infectious Diseases 13, 77-88.
- Ralph, A.P., Fittock, M., Schultz, R., Thompson, D., Dowden, M., Clemens, et al. (2013). Improvement in rheumatic fever and rheumatic heart disease management and prevention using a health centre-based continuous quality improvement approach. BMC Health Services Research, 13, 525.
- Ralph, A.P., Kenangalem, E., Waramori, G., Pontororing, G.J., Sandjaja, Tjitra, E., et al. (2013). High morbidity during treatment and residual pulmonary disability in pulmonary tuberculosis: under-recognised phenomena. PLoS One, 8(11).
- Ralph, A.P., & Lucas, R.M,. Vitamin D and tuberculosis: hope or hype? Medical Journal of Australia,199(10), 648-9.
- Ralph, A.P., Yeo, T.W., Salome, C.M., Waramori, G., Pontororing, G.J., Kenangalem, E., et al. (2013). Impaired Pulmonary Nitric Oxide Bioavailability in Pulmonary Tuberculosis: Association with Disease Severity and Delayed Mycobacterial Clearance with Treatment. Journal of Infectious Diseases, (4), 616-26.
- Pontororing, G.J., Kenangalem, E., Lolong, D.B., Waramori, G., Sandjaja, Tjitra, E., Price, et al. (2010). The burden and treatment of HIV in tuberculosis patients in Papua Province, Indonesia: a prospective observational study. BMC Infectious Diseases, 10, 362.
- Ralph, A.P., Ardian, M., Wiguna, A., Maguire, G.P., Becker, N.G., Drogumuller, G., et al. (2010). A simple, valid, numerical score for grading chest X-ray severity in adult smear positive pulmonary tuberculosis. Thorax, 65, 863-869.
- Ralph, A.P., Anstey, N.M., & Kelly, P.M. (2009). Tuberculosis into the 2010s: is the glass half full? Clinical Infectious Diseases, 49(4),574-83.
- Ralph, A.P., Kelly, P.M., & Anstey, N.M. (2008). Arginine and Vitamin D: novel adjunctive immunotherapies in tuberculosis. Trends Microbiology, 16(7):336-344.
Click here to view more Anna Ralph publications in PubMed.
Australian researchers have uncovered a link between low levels of the gas nitric oxide in the lungs of tuberculosis patients and the bodyís ability to fight the deadly disease, opening the door to potential new treatments.
Journal of Infectious Diseases: Impaired Pulmonary Nitric Oxide Bioavailability in Pulmonary Tuberculosis
Impaired Pulmonary Nitric Oxide Bioavailability in Pulmonary Tuberculosis: Association with Disease Severity and Delayed Mycobacterial Clearance with Treatment.
New research from the Menzies School of Health Research could open the door to the development of new treatments for Tuberculosis (TB).
With a history as long as mankindís, TB lies dormant in one third of our global population.